| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6036942 | COVIS | Seal configuration for aerosol canister |
Apr, 2013
(11 years ago) | |
| US5605674 | COVIS | Medicinal aerosol formulations |
Feb, 2014
(10 years ago) | |
| US5683677 | COVIS | Medicinal aerosol formulations |
Nov, 2014
(9 years ago) | |
| US5775321 | COVIS | Seal configuration for aerosol canister |
Jul, 2015
(8 years ago) | |
| US6006745 | COVIS | Device for delivering an aerosol |
Dec, 2016
(7 years ago) | |
| US6264923 | COVIS | Medicinal aerosol formulation of ciclesonide and related compounds |
May, 2018
(5 years ago) | |
| US6120752 | COVIS | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
May, 2018
(5 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) | |
Alvesco is owned by Covis.
Alvesco contains Ciclesonide.
Alvesco has a total of 9 drug patents out of which 8 drug patents have expired.
Expired drug patents of Alvesco are:
- US6036942
- US5605674
- US5683677
- US5775321
- US6006745
- US6264923
- US6120752
- US5482934
Alvesco was authorised for market use on 10 January, 2008.
Alvesco is available in aerosol, metered;inhalation dosage forms.
Alvesco can be used as method of treating inflammatory conditions, maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child.
Drug patent challenges can be filed against Alvesco from 20 October, 2010.
The generics of Alvesco are possible to be released after 01 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
| M(M-125) | Dec 17, 2015 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 10 January, 2008
Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child; Method of treati...
Dosage: AEROSOL, METERED;INHALATION
ALVESCO family patents
